Market Access Barriers Deterring New China R&D Investment: AmCham
This article was originally published in PharmAsia News
Executive Summary
Market access barriers are deterring 80% of US R&D-intensive industries, including pharma, from investing further in China, and many are pessimistic about the future regulatory environment in the country, says a just released business climate survey.
You may also be interested in...
As Trump Meets Xi, Executives Face Changing Dynamics In China
China is aggressively driving up life sciences innovations, leading the charge in technologies including gene editing and genome testing, prompting executives to take a fresh approach.
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.
Ready, Set, Go: China To Use Patient-Reported Outcomes In Clinical Studies
As a part of real-world evidence, patient-reported outcomes can serve to evaluate a drug's efficacy against primary or secondary endpoints and also reflect safety and quality of life, notes a just-released draft regulation from China’s Center for Drug Evaluation.